August 16, 2026 — As pharmaceutical manufacturers face increasing pressure to improve product consistency, process efficiency and quality control, controlling the physical properties of pharmaceutical powders and particles has become an increasingly important part of modern formulation development. Differences in particle size, particle shape, agglomeration behavior and dispersion characteristics can significantly influence powder flowability, blending performance, dissolution behavior and ultimately the consistency of finished pharmaceutical products.

To address these challenges, German particle characterization specialist NewPatek has developed an integrated analytical approach combining dry laser diffraction, dynamic image analysis and online particle monitoring. The solution is designed to provide pharmaceutical manufacturers with a more comprehensive understanding of powder behavior while improving measurement repeatability, defect traceability and production efficiency.

Powder Differences Can Create Significant Quality Variations

Pharmaceutical formulations often contain multiple powders with different physical properties. Active pharmaceutical ingredients, excipients and other functional materials may vary considerably in particle size distribution, morphology, density and surface characteristics.

Even when the chemical composition of a formulation remains unchanged, differences in these physical properties can affect the behavior of powders during feeding, transportation, mixing and compression.

Particle size is particularly important. Fine particles may have a higher tendency to agglomerate, while larger particles can behave differently during blending and segregation. If the particle population is not sufficiently controlled, variations can occur during the manufacturing process, potentially affecting content uniformity and downstream product performance.

Particle shape adds another layer of complexity. Two powders can have similar particle-size distributions but behave differently because their particles have different morphologies.

Traditional particle-size measurements alone may therefore provide only part of the information required to understand pharmaceutical powder behavior.

Dry Laser Diffraction Enables Rapid Dispersion Measurement

NewPatek's dry dispersion approach is designed for pharmaceutical powders that are difficult or undesirable to measure using conventional wet-dispersion methods.

Dry measurement eliminates the need to suspend samples in a liquid, reducing sample preparation requirements and avoiding potential changes to particles caused by liquid interaction.

For pharmaceutical manufacturers, this can be particularly useful when working with water-sensitive materials, powders with poor wetting characteristics or samples for which rapid screening is required.

The system uses controlled airflow to disperse powder particles before laser diffraction measurement. By producing a controlled and repeatable dispersion environment, the technology can help reduce the influence of manual sample preparation on measurement results.

The result is a faster analytical workflow that can support both laboratory development and routine quality-control applications.

Particle Size and Shape Need to Be Evaluated Together

While laser diffraction provides valuable information about particle-size distribution, pharmaceutical powder characterization increasingly requires additional morphological information.

NewPatek's integrated solution combines laser diffraction with dynamic image analysis to evaluate particle size and shape simultaneously.

Dynamic image analysis captures images of individual particles as they move through the measurement system. These images can then be analyzed to obtain information about particle dimensions, morphology and shape-related parameters.

This provides a different perspective from conventional bulk particle-size measurement.

For example, two samples may show comparable particle-size distributions while containing different proportions of elongated, irregular or agglomerated particles. Image analysis can help identify these differences and provide additional evidence for understanding variations in powder behavior.

For pharmaceutical manufacturers, combining size and shape information can make it easier to identify potential sources of formulation variability.

From Measurement to Defect Traceability

One of the major advantages of an integrated characterization strategy is the ability to move beyond a single measurement value and investigate the potential origin of abnormal results.

When a batch demonstrates unexpected particle-size or shape characteristics, manufacturers need to determine whether the problem originates from raw materials, milling, granulation, blending, transportation or another stage of the production process.

Particle characterization can provide an important analytical link between process conditions and physical powder properties.

If an unusual particle population is detected, image-based analysis can help identify whether the deviation is associated with oversized particles, fines, agglomerates or abnormal particle morphology.

This creates a more detailed evidence base for process troubleshooting.

Instead of simply recording that a batch has failed to meet a particle-size specification, manufacturers can investigate what type of particles are responsible and determine where corrective action may be required.

Online Monitoring Extends Control Beyond the Laboratory

Another important element of the NewPatek approach is online particle monitoring.

Conventional laboratory testing provides valuable information, but samples are typically collected at specific points in time. A production process, however, can change continuously.

Raw-material feeding rates, milling conditions, granulation parameters, airflow and other process variables can influence particle characteristics during manufacturing.

Online monitoring offers the possibility of observing particle behavior closer to the actual production process.

By integrating particle measurement into process monitoring, manufacturers can identify changes earlier and potentially reduce the time between the appearance of a deviation and the implementation of corrective action.

This approach is consistent with the broader pharmaceutical industry's movement toward process analytical technology, continuous manufacturing and data-driven quality management.

Improving Repeatability and Reducing Measurement Costs

Measurement repeatability is another important consideration in pharmaceutical particle characterization.

Manual sample preparation can introduce operator-to-operator differences. Variations in sample feeding, dispersion and handling can influence analytical results, particularly when powders have strong cohesive properties.

A controlled dry-dispersion workflow can help reduce some of these variables.

For laboratories conducting large numbers of measurements, faster preparation and shorter measurement cycles may also reduce analytical workload and operating costs.

The economic benefit is not limited to the measurement itself. Better characterization can contribute to earlier identification of problematic raw materials and process deviations, potentially reducing the cost associated with failed batches, repeated testing and unnecessary process adjustments.

Supporting More Consistent Pharmaceutical Production

The ultimate objective of particle characterization is not simply to generate analytical data. It is to help manufacturers understand how particle properties influence the performance and consistency of pharmaceutical processes.

By combining dry laser diffraction, dynamic image analysis and online monitoring, NewPatek's approach provides multiple levels of information.

Dry laser diffraction can provide rapid particle-size distribution data.

Dynamic image analysis can add detailed information about individual particle morphology.

Online monitoring can connect particle characteristics with changing process conditions.

Together, these technologies can create a more comprehensive particle-characterization framework for pharmaceutical development and manufacturing.

Such an approach can be particularly valuable when conventional particle-size testing cannot fully explain variations in powder behavior.

From Raw Materials to Finished Formulations

The potential applications extend across multiple stages of pharmaceutical production.

During raw-material qualification, particle-size and shape information can help manufacturers compare incoming materials and establish physical-property specifications.

During formulation development, particle characterization can help researchers understand how different excipients and active ingredients interact during mixing and processing.

During process development, measurement data can support optimization of milling, granulation and blending parameters.

During manufacturing, online monitoring can provide additional information about process stability.

For quality control, repeatable measurement workflows can help laboratories establish more consistent analytical procedures.

This broad application range reflects a fundamental change in pharmaceutical powder analysis: particle characterization is increasingly becoming part of the entire production lifecycle rather than a single laboratory test performed at the end of a process.

A More Integrated Approach to Powder Quality

As pharmaceutical manufacturing becomes more automated and data-driven, the ability to connect particle characteristics with process behavior will become increasingly important.

The combination of dry dispersion, laser diffraction and dynamic image analysis provides manufacturers with complementary information rather than relying on a single analytical parameter.

At the same time, online monitoring can help bridge the gap between laboratory characterization and real-world production.

For manufacturers dealing with formulation variability, powder segregation, agglomeration or inconsistent blending performance, this integrated approach offers a pathway toward more precise investigation and process control.

NewPatek's solution demonstrates how advances in particle characterization can contribute to the pharmaceutical industry's broader objective of improving batch-to-batch consistency while reducing analytical complexity and operational costs.

Ultimately, the challenge of pharmaceutical powder uniformity cannot be solved by particle-size measurement alone. Understanding how particles are sized, shaped, dispersed and continuously distributed through a process provides a more complete picture.

By bringing these analytical capabilities together, NewPatek is positioning particle characterization as a practical tool for identifying variability, tracing defects and supporting more reliable pharmaceutical manufacturing.